Key Takeaways
- Profitability, not revenue, is the story: Revenue grew just 4% but EBITDA rose 33% and PAT 64%, driven by a deliberate shift from low-margin B2B API to higher-value consumer-facing products and exports.
- Medical devices are the compounding engine: An installed base of 13 crore meters drives recurring strip sales, with strips per meter rising to ~165; the segment is targeted to grow at a 25–26% CAGR.
- API degrowth was strategic, not structural: A 9% API revenue decline came from walking away from low-price trader sales in India, not from losing major customers; a direct-sales team is now being built to recapture margin.
- A 40-year EBITDA record was broken: Four consecutive quarters have now averaged ₹50 crores+ in EBITDA, a first in the company's history, with H1 margins at 11.55% and a path laid to 15% in three years.
- What to watch next quarter: Whether the Baddi finished-dosage facility moves from validation batches to order bookings, the pace of API recovery in the seasonally stronger H2, and any concrete update on the promised weight-loss product launch.
The Strategic Pivot: B2B to B2C
- Core repositioning: The company is shifting from a traditional API B2B model toward a consumer-facing portfolio of medical devices, branded finished dosages, and high-value exports, aiming for better returns, higher P/E multiples, and a long-term brand.
- Domestic API pullback: Revenue from the India API market was deliberately reduced by 9%, costing ~₹30 crores in topline but improving overall profitability; a Mumbai-based team is now selling directly to customers, cutting out traders to capture better margins.
- Export mix driving margin: H1 exports grew 20%, led by Europe (+60%) and the US (+5%), while the low-margin domestic business was shrunk; this mix shift is the primary driver of the 33% EBITDA jump on just 4% revenue growth.
- Category leadership cemented: Market share gains across key molecules: Montelukast moved from 44% to 70%, Fexofenadine from 22% to 31%, Loratadine from 64% to 69%, and Desloratadine from 42% to 49%.
- New molecules as growth accelerant: The diabetic portfolio contribution rose from ~10% to 13.6% of H1 revenue; management expects new molecules to grow 2x, 3x, or 5x as patents expire and markets open, far outpacing the 10–15% growth of older category leaders.
Sushil Suri: "There is a complete shift in the overall strategy of the company. And as we all know that traditionally Morepen had been an API player. So we have been working on a B2B business model... It's only last couple of years that we have been able to get good headway in the consumer business also."
Medical Devices: The Installed-Base Flywheel
- Installed base growth: 25 lakh meters were added in the past year, taking the total installed base from 10.5 crores to 13 crores; this base generates recurring, high-margin strip sales that are the segment's profit engine.
- Strip consumption rising: Strips sold grew ~10% to 22.1 crores, and strips consumed per meter increased from ~150 to ~165, indicating higher usage per customer as the base matures.
- BP monitor backward integration complete: An SMT machine now enables 100% self-manufacturing of BP monitors, eliminating dependence on Chinese imports and turning a previously breakeven product profitable.
- Capacity constraints resolved: Medical device growth was flat in Q1 and Q2 because production lines were shifted to SMT manufacturing; capacity is now balanced and the segment is expected to hit its full-year target of ₹545–550 crores.
- New device launches: Nebulizer production started this quarter after receiving a license, with ₹25–30 crores in expected revenue; ortho support systems are now manufactured in-house; a Bluetooth glucometer with a voice-enabled companion app is launching next quarter.
- Export registration unlocked: USFDA and Health Canada Class 1 medical device registration is complete, opening the US and Canadian markets where retail price points start at $15–$20 versus $2–$5 in India.
Sushil Suri: "Our selling price in India at retail level is $2, $3, $5. So there the starting point is between $15 to $20. So it's much higher."
API: Strategic Degrowth, Not Customer Loss
- The 9% decline explained: API revenue fell from ₹143 crores to ₹130 crores YoY entirely because of a decision to stop selling through traders at depressed prices; major customers like Cadila, Sun Pharma, Cipla, and Mankind remain intact.
- Pricing discipline in action: Management cited Montelukast as an example: the price swung from ₹35,000 to ₹58,000 during COVID and back to ₹30,000–32,000; when traders demanded ₹26,000, Morepen walked away rather than destroy category pricing.
- South America tender loss: A previously won tender was not repeated because the customer could not secure the tender at their desired price and did not buy from Morepen; this is a small market at 5% of total revenue.
- Seasonal tailwind ahead: API performance is always stronger in H2, with Q3 driven by annual closing buying and Q4 by foreign customer purchases; management expects a much better second half.
- Capacity expansion underway: API capacity is expanding from 400 KL to 600 KL, with 50 KL already implemented; the balance is expected to complete this quarter, with volume upside from next quarter onward.
Sushil Suri: "Being a market leader if Morepen reduces price for example, Montelukast as an example normal running price of Montelukast some years ago was like INR35,000. During COVID time, it reached up to INR58,000. From INR58,000, it came down to back to INR32,000, INR30,000. And if someone asking me INR26,000, I can't give it."
Margins: A Record Run, With a Roadmap
- Four-quarter milestone: For the first time in 40 years, Morepen has posted four consecutive quarters averaging ₹50 crores+ in EBITDA, with cumulative EBITDA of ₹211 crores over the period.
- H1 margin expansion: EBITDA margin reached 11.55% in H1 FY25, up from 10.13% in H1 FY24 and just 6% in FY23; the improvement comes from mix shift toward higher-margin devices and exports, not cost-cutting.
- The 15% target: Management is targeting 15% EBITDA in the next three years, rising to 17–18% in five years, driven by the growing share of consumer-facing revenue and operating leverage from new facilities.
- H2 margin confidence: Management expects to maintain H1 margins in the second half, with the caveat that Q4 is typically weaker for medical devices and stronger for API.
Sushil Suri: "It is for the first time in the history of last 40 years that collective four quarters, we are getting a INR50 crores plus EBITDA on an average."
Capex, Facilities & The 2030 Vision
- QIP deployment: The ₹200 crores QIP, which closed in August 2024 with participation from Bank of America, Samsung, Citigroup, and others, is funding a capex cycle targeted for completion in 18–24 months, by end of FY26.
- Baddi finished-dosage facility: The plant is commissioned and validation batches have started after regulatory delays; management expects to begin booking orders within 12–18 months, adding capacity of 120 crore dosages.
- Medical device facility expansion: A new 120,000 sq ft facility (five times the current 30,000 sq ft) has civil work completing this quarter, with machine installation to follow.
- 2030 revenue ambition: The company is targeting ₹5,000 crores in topline by 2030 at a ~20% CAGR, with medical devices growing faster to reach a 40:60 revenue mix (devices:pharma).
- Medical device demerger: The device business is being moved into a separate subsidiary; the regulatory process is expected to finish between this quarter and next quarter, after which the new entity will have its own growth plans.
- Strategic silence on further moves: Management hinted at undisclosed plans, saying "a lot cooking in" and that the next two quarters will bring clearer strategic direction on fundraising and value unlocking.
Sushil Suri: "I would say a lot cooking in. So I have to keep quiet on certain things."
Pushback & Unanswered Questions
- Europe outlet count undisclosed: When asked for the number of outlets achieved against the 3-lakh-in-three-years target, management declined to share, saying full details will come only in the annual presentation.
- Weight-loss product launch delayed: Previously announced for the festival season, the product is now listed as "coming soon"; management said the team is not ready to disclose details and it will "come as a surprise."
- No near-term revenue guidance: When asked for FY25 revenue guidance, management declined to give a number, instead emphasizing the focus on profitability and yield over topline.
- Tariff impact unevaluated: An analyst asked whether new US tariffs would affect the Class-I device export business; management said they had not evaluated the specific tariff and would need to revert.
- Promoter stake increase: intent without a plan: Management said promoters want to increase their stake but have no specific plans in place.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| QIP capex cycle completion | All expansion projects from QIP funds finished | 18–24 months, by end of FY26 |
| Baddi facility order bookings | Validation and filings complete, orders begin | 12–18 months |
| Medical devices CAGR | 25–26% growth | Sustained over medium term |
| Overall company CAGR | ~20% | To FY30 |
| Revenue target | ₹5,000 crores topline | By 2030 |
| EBITDA margin target | 15% | In next three years |
| EBITDA margin target | 17–18% | In next five years |
| Medical device revenue share | 40% of total revenue (40:60 devices:pharma) | By 2030 |
| API capacity expansion | 400 KL to 600 KL; 50 KL done, balance this quarter | Volume upside from next quarter onward |
| Medical device demerger | Regulatory process complete, separate subsidiary operational | Between this quarter and next quarter |
| Medical devices FY25 revenue | ₹545–550 crores | FY25 |
| Strategic direction clarity | Clear direction on fundraising and value unlocking | Next two quarters |
| Medical representative expansion | From ~200 to 1,000 | Next five years |
| Branded finished-dosage network | Pan-India expansion | Next three years |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Revenue | ₹443 cr, +4% YoY |
| H1 Revenue | ₹901 cr, +9% YoY |
| EBITDA | ₹49 cr, +33% YoY |
| H1 EBITDA | ₹104 cr, +59% YoY |
| EBITDA margin | 11.55% in H1, up from 10.13% in FY24 |
| Profit after tax | ₹35 cr, +64% YoY |
| H1 PAT | ₹71 cr |
| Quarterly EPS | ₹0.65 |
| TTM EPS | ₹2.53 |
| Pharma segment H1 revenue | ₹630 cr, +9% YoY |
| Medical devices H1 revenue | ₹271 cr, flat YoY |
| Export growth in H1 | +21% YoY, to ₹337 cr |
| Installed glucometer base | 1.3 cr meters, up from 1.06 cr a year ago |
| Strips sold in H1 | 22.1 cr strips, +10% YoY |
| Strips per meter | ~165, up from ~150 a year ago |
| BP monitors sold in H1 | ~3 lakh units, vs 3.1 lakh a year ago |
| New product contribution | 13.6% of pharma revenue in H1, up from ~10% a year ago |
| QIP balance remaining | ₹137 cr as of 30 Sep 2024 |